Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan-Octreotide LAR Combination in ADPKD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (\>18-yr-old) men and women, with a clinical and ultrasonographic diagnosis of ADPKD;~2. Serum creatinine \< 1.0 mg/dl (for man) and \< 1.2 mg/dl (for woman) and changes in serum creatinine (and creatinine clearance when available) \<30% over the last six months;~3. Creatinine clearance \> 80 ml/min/1.73m2 measured one to two weeks apart during the pre-screening period;~4. GFR ≥ 80 ml/min/1.73m2 (by iohexol plasma clearance technique) at screening and baseline evaluations;~5. TKV ranging between 1000 and 2000 ml at screening (by ultrasound imaging) and at baseline (by MRI) evaluations;~6. Female participants must be of non-childbearing potential or must agree to abstinence or use a highly effective form of contraception;~7. Written informed consent.~Exclusion Criteria:~1. Patients with concomitant systemic, renal parenchymal or urinary tract disease;~2. Diabetes;~3. Overt proteinuria (urinary protein excretion rate \>1 g/24 hours);~4. Abnormal urinalysis suggestive of concomitant, clinically significant glomerular disease, urinary tract lithiasis, infection or obstruction, biliary tract lithiasis or obstruction;~5. Hemorrhagic or complicated cysts which might acutely affect kidney function and volumes;~6. QT-related ECG abnormalities;~7. Cancer and major systemic diseases that could prevent completion of the planned follow-up or interfere with data collection or interpretation;~8. Hypersensitivity to the IMP active substance or to any of the excipients or to benzazepine or benzazepine derivatives;~9. Concomitant treatment with drugs that may affect glomerular hemodynamics during the three months before the beginning of the study (including ACE inhibitors, angiotensin receptor blockers, aldosterone antagonists and non-steroideal anti-inflammatory medications);~10. Elevated liver enzymes and/or signs or symptoms of liver injury prior to initiation of treatment that meet the requirements for permanent discontinuation of tolvaptan~11. Patients with anuria, volume depletion and hypernatraemia~12. Patients who cannot perceive or respond to thirst~13. Ferro-magnetic prosthesis, aneurysm clips, severe claustrophobia or any other contraindication to MRI evaluation;~14. Psychiatric disorders and any condition that could prevent full comprehension of the purposes and risks of the study;~15. Pregnant or lactating;~16. Participation in another interventional clinical trial within the 4 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo (Type: EXPERIMENTAL): Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)
- Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR (Type: EXPERIMENTAL): Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).

Based on this trial design, predict the completion outcome and termination type (if applicable).